NOTE: To place order using Credit Card, P-Card, or Purchase Order – please choose kit size above and click “Add to cart” button. You can place order online without creating an account.
Transfection Reagent for H9c2 Cells (Rat Embryonic Myocardium Cells, CRL-1446)
Proprietary cationic lipids formulation
High transfection efficiency of small RNA (siRNA, shRNA, miRNA), mRNA, pDNA
Kit includes Transfection Enhancer reagent
A proven reagent for establishing H9c2 stable cell lines
Optimized transfection protocols are adapted for use with both standard & reverse transfection methods
- Download PowerPoint presentation for H9C2 cells transfection kit: [PPT]
Developed and manufactured by Altogen Biosystems
Reagent exhibits at least 82% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.
Transfection Protocol and MSDS:
Download Altogen Biosystems H9C2 Transfection Protocol: [PDF]
Download MSDS: [PDF]
H9c2 Cell Line:
The H9c2 cell line was established from embryonic BD1X rat (Rattus norvegicus) heart tissue. It exhibits a myoblast morphology as well as possesses many skeletal muscle properties. This cell line could be useful for studying the heart tissue of mammals, and in a variety of specialized research related to molecular and cellular biology. H9c2 expresses the acetylcholine receptor, and frequently used in biomedical research as a transfection host cell line.
Figure 1. GAPD mRNA levels were quantified using real-time RT-PCR in the H9C2 cells transfected with siRNAs targeting GAPD or non-silencing siRNA. Forty-eight hours post-transfection, the cells were harvested and analyzed by real-time RT-PCR for GAPD mRNA expression levels. Data were normalized against the 18S rRNA signal. Control samples were either mock-transfected or untreated. Values are normalized to untreated sample. Data are means ± SD (n=5).
Figure 2. Protein expression of GAPDH in H9c2 cells. DNA plasmid expressing GAPDH or siRNA targeting GAPDH were transfected into H9c2 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.
Altogen Biosystems provides pre-optimized transfection kits and electroporation products for life sciences and cancer research. Transfection protocols are optimized for individual cancer cell lines. Altogen Biosystems developed two types of in vivo delivery kits (animal transfection): 1) Tissue-targeted reagents (delivery of proteins, DNA, and RNA into liver, pancreas, or kidney tissues), and 2) Broad range in vivo biodistribution reagents (PEG-Liposome based reagent, Nanoparticle-based in vivo reagent, Lipid-based transfection kit, and Polymer-based kit). Advanced formulation of reagents and optimized transfection protocols provide efficient intracellular delivery of proteins, DNA, mRNA, shRNA, siRNA, and other negatively charged biomolecules in vitro and in vivo. Read more about transfection technology at Altogen’s Transfection Resource.
Altogen Labs Research Services:
Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (30+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).
- 0.5 ml (Catalog #6805)
- 1.5 ml (Catalog #6806)
- 8.0 ml (Catalog #7040)